News
Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform
Evotec: Es regnet Millionen dank Bayer – wieder mal!
Vor zwei Tagen machte Evotec (WKN: 566480) die Erweiterung seiner iPSC-Allianz mit Bristol-Myers Squibb öffentlich (wir berichteten). Heute meldet der Hamburger Biotechkonzern eine „neue
Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases
Evotec: Das hören Anleger gern
Es sind Meldungen wie diese, die Anleger in Evotec-Aktien (WKN: 566480) jubeln lassen. Wie gestern bekannt gegeben, erweitert Evotec die Forschungsallianz mit dem Global Player Bristol-Myers Squibb
Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update
Regulatory News:
“After the achievement of major development milestones in 2019, 2020 offers great opportunity for Nanobiotix and NBTXR3 to fulfill unmet patient needs across oncology. Given
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 38th Annual J.P. Morgan
Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
pioneering a new way to treat the underlying cause of severe genetic
diseases by precisely upregulating protein
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019
Clovis
Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary,
unaudited revenues for the fourth quarter and full year ended December
31, 2019. The financial
Clovis Oncology Announces Debt Refinancing Transaction
Clovis Oncology, Inc. (NASDAQ: CLVS) (the “Company”) announced today that on January 6, 2020 it priced a registered direct offering (the “Share Offering”) of an aggregate of 17,777,679 shares (the
Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:
Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery
Cellectis
(Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth:ALCLS; Nasdaq:CLLS), a
biopharmaceutical company focused on developing immunotherapies based on
gene-edited
The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75%
Biofrontera: Bald könnte es Top-Neuigkeiten geben
Der Dermatologie-Spezialist Biofrontera (WKN: 604611) sah sich zuletzt einer schwindenden Umsatzdynamik gegenüber. Einer der Schlüsselfaktoren ist der Absatz des verschreibungspflichtigen
Clinigen and Orphazyme launch an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Orphazyme A/S (ORPHA.CO, ‘Orphazyme’), a global biopharmaceutical company dedicated to
Charles River Laboratories Completes the Acquisition of HemaCare Corporation
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately $380
Pulmatrix: NBC-Empfehlung explodiert nach Big-Pharma-Deal
Für den No Brainer Club überträgt sich das gigantische Momentum von Ende 2019 ohne Unterbrechung ins neue Jahr: Mit Pulmatrix (WKN: A2PD3T) explodiert heute einer der letzten unten gebliebenen No
LION E-Mobility: Nach dem Deal ist vor der Rallye?
LION E-Mobility (WKN: A140QA) hatte mit der kanadischen Firma "The Lion Electric Co." vor Weihnachten einen „Multimillionen-Serienliefervertrag über BMW-Batterien“ geschlossen. Nun gibt das
Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled
Cidara und Otonomy: Weitere NBC-Favoriten knallen durch die Decke
Aktien von Cidara Therapeutics (WKN: A14R2R) und Otonomy (WKN: A119VZ) gehörten vergangene Woche mal wieder zu den Gewinnern im Biotech-Sektor. Stehen hier ähnliche Entwicklungen an wie jüngst bei
Paion: Erste Zulassung zum Greifen nah - jetzt einsteigen?
Weltweit laufen bei Paion (WKN: A0B65S) Zulassungsanträge für den potenziellen Anästhesie-Blockbuster Remimazolam, doch die Aktie notiert auf Langzeittief. Die erste Zulassung des Präparatss könnte
LION E-Mobility: Serienliefervertrag für E-Schulbusse fix
LION E-Mobility (WKN: A140QA) wird Serienlieferant von Batterien für E-Schulbusse und E-LKWs. Dazu schloss das Unternehmen einen „potentiellen Multimillionen-Serienliefervertrag über BMW-Batterien“.
Qiagen: Übernahme geplatzt – so kann es jetzt weitergehen
Qiagen-Aktien (WKN: A2DKCH) verbilligen sich heute um -18,93% auf 30,02 Euro. Der Grund sind gescheiterte Übernahmegespräche.
Die Gespräche mit möglichen Übernahme-Interessenten würden nun beendet